Evotec SE Ownership
EVOTF Stock | USD 9.34 2.57 37.96% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Evotec |
Evotec Pink Sheet Ownership Analysis
About 66.0% of the company shares are held by institutions such as insurance companies. The book value of Evotec SE was currently reported as 6.95. The company has Price/Earnings (P/E) ratio of 347.66. Evotec SE had not issued any dividends in recent years. The entity had 50:1 split on the 3rd of June 1999. Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. EVOTEC SE operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4521 people.The quote for Evotec SE is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Evotec SE call MBA MBA at 49 40 560 81 0 or check out https://www.evotec.com.Currently Active Assets on Macroaxis
Other Information on Investing in Evotec Pink Sheet
Evotec SE financial ratios help investors to determine whether Evotec Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evotec with respect to the benefits of owning Evotec SE security.